Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member
01 mars 2022 16h05 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert...
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
24 févr. 2022 07h00 HE
|
Lantheus Holdings, Inc.
Worldwide revenue of $129.6 million and $425.2 million for the fourth quarter and full year 2021, representing an increase of 37.6% and an increase of 25.3% over the prior year period,...
Lantheus Receives U.S. FDA Approval of New Manufacturing Facility
23 févr. 2022 08h00 HE
|
Lantheus Holdings, Inc.
On-site plant will produce DEFINITY® (Perflutren Lipid Microsphere), the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms NORTH BILLERICA, Mass., Feb. 23,...
Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting
10 févr. 2022 17h33 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on February 24, 2022 at 8:00 a.m. Eastern Time
10 févr. 2022 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on...
Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer
27 janv. 2022 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a...
Lantheus Appoints Vivian Yao as Chief Human Resources Officer
01 déc. 2021 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces PYLARIFY AI™ is Now Available
29 nov. 2021 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging...
Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022
22 nov. 2021 08h30 HE
|
Lantheus Holdings, Inc.
PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings,...
Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific Meetings
17 nov. 2021 08h30 HE
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging...